Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259096 | 0.89 | CDK2 (0.34) | CDK2PTGS2HTR2AALDH1A1MEN1 | |
| SCHEMBL13258421 | 0.84 | PTGS2 (0.37) | CDK2PTGS2HTR2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15267556 | 0.83 | ALDH1A1 (0.47) | CDK2PTGS2HTR2AALDH1A1MEN1 | |
| SCHEMBL19114665 | 0.83 | HTR2A (0.34) | CDK2PTGS2TGFBR1HTR2AALDH1A1 | |
| SCHEMBL13258414 | 0.82 | HTR2A (0.34) | CDK2PTGS2HTR2AALDH1A1MEN1 | |
| SCHEMBL13258427 | 0.82 | HTR2A (0.43) | CDK2HTR2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13258411 | 0.81 | PTGS2 (0.30) | PTGS2 | |
| SCHEMBL8068972 | 0.81 | CDK2 (0.49) | CDK2PTGS2HTR2AALDH1A1MEN1 | |
| SCHEMBL15267231 | 0.80 | PTGS2 (0.30) | PTGS2 | |
| SCHEMBL13258483 | 0.80 | PTGS2 (0.30) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393801-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| US-8541442-B2 | Indole derivatives as anticancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8541442-B2 | Indole derivatives as anticancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | Janssen Pharmaceutica NV a corporation | 2011-12-01 | — | — | US | disclosed |
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | Janssen Pharmaceutica NV a corporation | 2011-12-01 | — | — | US | disclosed |
| WO-2010089327-A2 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | IDO1, IDO2, INMT | CDK2 114/4885PTGS2 686/4885TGFBR1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.